Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.

TEVA

Teva Pharmaceutical Indu... (TEVA)

Teva Pharmaceutical Industries Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:TEVA
DateHeureSourceTitreSymboleSociété
29/04/202302h22Business WireTeva et MedinCell annoncent l'approbation par la FDA américaine de UZEDY™ (risperidone), un antipsychotique sous forme de suspension injectable sous-cutanée à libération prolongée pour le traitement de la schizophrénie chez l'adulteNYSE:TEVATeva Pharmaceutical Industries Ltd
29/04/202302h22Business WireTeva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in AdultsNYSE:TEVATeva Pharmaceutical Industries Ltd
27/04/202314h35Business WireTeva to Launch New Growth Strategy at Investor DayNYSE:TEVATeva Pharmaceutical Industries Ltd
19/04/202322h18Edgar (US Regulatory)Annual Report to Security Holders (ars)NYSE:TEVATeva Pharmaceutical Industries Ltd
19/04/202322h13Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NYSE:TEVATeva Pharmaceutical Industries Ltd
14/04/202322h15Business WireTeva to Host Conference Call to Discuss First Quarter 2023 Financial Results at 8 a.m. ET on May 10, 2023NYSE:TEVATeva Pharmaceutical Industries Ltd
14/04/202320h28Dow Jones NewsTeva Shares Drop 11% After Alvotech Gets FDA Complete Response LetterNYSE:TEVATeva Pharmaceutical Industries Ltd
14/04/202302h53Business WireComplete Response Letter Received for AVT02 Biologics License ApplicationNYSE:TEVATeva Pharmaceutical Industries Ltd
11/04/202314h00Business WireTeva to Present New Data on Once-Daily AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets at the 2023 American Academy of Neurology Annual MeetingNYSE:TEVATeva Pharmaceutical Industries Ltd
27/03/202314h00Business WireTeva’s Digital Health Collaboration with Rimidi Expands to Include Respiratory Monitoring Program Integration with a Large U.S. Health SystemNYSE:TEVATeva Pharmaceutical Industries Ltd
13/03/202314h33Business WireTeva Announces Early Tender Results of its Debt Tender Offer, Increases to Tender Caps and Election of Early SettlementNYSE:TEVATeva Pharmaceutical Industries Ltd
09/03/202323h19Edgar (US Regulatory)Current Report Filing (8-k)NYSE:TEVATeva Pharmaceutical Industries Ltd
09/03/202314h00Business WireTeva and Natco Announce Launch of additional strengths for the Generic Version of Revlimid® (lenalidomide capsules), in the U.S.NYSE:TEVATeva Pharmaceutical Industries Ltd
08/03/202322h06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:TEVATeva Pharmaceutical Industries Ltd
07/03/202322h00Business WireTeva to Present at the Barclays Global Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
03/03/202313h03Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NYSE:TEVATeva Pharmaceutical Industries Ltd
01/03/202322h13Edgar (US Regulatory)Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)NYSE:TEVATeva Pharmaceutical Industries Ltd
01/03/202322h11Business WireTeva Announces Successful Upsize and Pricing of $2,490,000,000 (equivalent) Sustainability-Linked Senior Notes and the Increase of the Maximum Tender Amount of its Debt Tender OfferNYSE:TEVATeva Pharmaceutical Industries Ltd
27/02/202309h30Business WireTeva Announces Launch of $2,060,000,000 (Equivalent) Offering of Sustainability-Linked Senior NotesNYSE:TEVATeva Pharmaceutical Industries Ltd
27/02/202309h30Business WireTeva Announces $2,250,000,000 Debt Tender Offers for Notes Due 2023-2026NYSE:TEVATeva Pharmaceutical Industries Ltd
24/02/202314h00Business WireTeva to Present New Data from CONNECT2 Study on its Digihaler® System at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual MeetingNYSE:TEVATeva Pharmaceutical Industries Ltd
23/02/202314h00Business WireTeva Announces Publication of New Clinician Scale in Journal of Clinical Psychiatry to Assess the Impact of Tardive Dyskinesia on Patients’ LivesNYSE:TEVATeva Pharmaceutical Industries Ltd
18/02/202300h03Dow Jones NewsTeva Gets FDA Approval for Movement Disorders TreatmentNYSE:TEVATeva Pharmaceutical Industries Ltd
17/02/202322h56Business WireTeva Announces FDA Approval of AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, a New Once-Daily Formulation of AUSTEDO® (deutetrabenazine) TabletsNYSE:TEVATeva Pharmaceutical Industries Ltd
13/02/202321h33Edgar (US Regulatory)Schedule 13g
(sc 13g/a)
NYSE:TEVATeva Pharmaceutical Industries Ltd
10/02/202313h04Edgar (US Regulatory)Annual Report (10-k)NYSE:TEVATeva Pharmaceutical Industries Ltd
09/02/202315h05Dow Jones NewsTeva to Pay Florida $6.7 Million to Settle Price-Fixing AllegationsNYSE:TEVATeva Pharmaceutical Industries Ltd
09/02/202314h00Business WireTeva Reaches Agreement With Florida to Settle the State’s Price Fixing ClaimsNYSE:TEVATeva Pharmaceutical Industries Ltd
08/02/202322h23Edgar (US Regulatory)Securities Registration (ads, Immediate) (f-6ef)NYSE:TEVATeva Pharmaceutical Industries Ltd
08/02/202313h00Business WireTeva Reports Fourth Quarter and Full Year 2022 Financial ResultsNYSE:TEVATeva Pharmaceutical Industries Ltd
 Showing the most relevant articles for your search:NYSE:TEVA